Press Room

From left to right: Jean-Luc Herbeaux, CEO of 四色AV, Paula Alves, CEO of iBET, and Jo茫o Almeida Lopes, President of iBET.   Lisbon, Portugal:鈥纳獳V, the specialist integrated CDMO and leader in spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnol贸gica), a private not-for-profit research-intensive SME in the area of Biotechnology and Life Sciences, are proud to announce the official establishment of ViSync庐 Technologies as a jointly owned venture. The creation of this new company, headquartered in the Lisbon area of Portugal, illustrates the parent companies麓 commitment to partnership and joint innovation. ViSync庐 will aim to develop innovative solutions to address the unmet technical needs of pharmaceutical companies in the cell and gene therapy space, leveraging 四色AV's extensive expertise in pharmaceutical development, Particle Engineering and industrialization of pharmaceutical technologies and iBET's cutting-edge research in biotechnological sciences. One of the first focus areas of ViSync庐 will be to develop technologies that improve delivery and stabilization of new modality therapies. "We are delighted to join forces with iBET - a leading R&D organization in Biotechnology and Life Sciences 鈥 in the establishment of ViSync庐.鈥 says Jean-Luc Herbeaux, 四色AV鈥檚 CEO. 鈥淏y combining 四色AV麓s expertise in drug formulation, manufacturing process development and scale up with iBET麓s broad understanding of new modalities, we aim to devise new solutions to help pharma companies launch innovative medicines and improve health outcomes for patients.鈥   鈥淭he creation of ViSync庐 marks a significant milestone for iBET.鈥 says Paula Alves, CEO of iBET. 鈥淏y combining our cutting-edge biotechnological research in the cell and gene therapy fields with 四色AV鈥檚 extensive pharmaceutical development expertise, we are well-positioned to develop innovative approaches for targeted delivery and stabilization of new modality therapies. We are excited about the potential of ViSync庐 to drive substantial advancements and deliver significant benefits to patients worldwide.鈥    About 四色AV  四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected鈥痵ites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥痙evelopment and compliant manufacture鈥痮f innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. 四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About iBET iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET鈥檚 core expertise lies on the development of bioprocesses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing.     iBET鈥檚 infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies.    iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders.    

Press Release
Commitment to partnership and joint innovation for cell and gene therapies

四色AV and iBET Announce the Establishment of ViSync庐 Technologies: A Venture in Cell and Gene Therapy Solutions

Sep 19, 2024

Lisbon, Portugal: 四色AV, the specialist integrated CDMO and leader in spray drying and particle engineering, is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.   The new line is the result of the partnership with GEA, a global leader in process technology for the pharmaceutical industry. Since announcing their partnership in 2022, 四色AV and GEA have worked to advance continuous tableting technology. Their collaboration seeks to boost the adoption of continuous tableting by offering increased capacity, flexibility, standardized equipment, improved quality, and enhanced efficiency. Together, they have shown that continuous tableting can become a more accessible technology. This new R&D line is the only one of its kind in the world and perfectly replicates the most critical components of 四色AV麓s state-of-the-art commercial CT line in Loures, Portugal. It also offers a high degree of flexibility in throughput and can handle highly potent Active Pharmaceutical Ingredients (API). 鈥淲ith this new line, we will be able to optimize operating conditions with minimum amounts of API and provide a higher technical certainty when transferring from development to commercial scale鈥, said Jaime Del Campo, Head of R&D Services at 四色AV. 鈥淭he flexibility of the rig and the real-time process data monitoring capabilities contribute to a more agile design and upscaling experience.鈥 The new CT line at 四色AV's Lisbon R&D center is now fully operational and ready to support both existing and new projects. This investment reinforces 四色AV's global reputation in pharmaceutical manufacturing and highlights the company's commitment to delivering innovative solutions that meet the evolving needs of the industry and support quicker and more efficient market launches.    About 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four鈥疐DA inspected鈥痵ites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥痙evelopment and compliant manufacture鈥痮f innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.     Learn more about Continuous Tableting for Drug Product    

Press Release
四色AV is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.

四色AV Unveils New Continuous Tableting Line at Lisbon R&D Centre

Jun 18, 2024

四色AV and GEA further strengthened their partnership, resulting in the launch of the ConsiGma庐 CDC flex Continuous Tableting Technology and the installation of a lab-scale R&D rig in 四色AV麓s facilities in Portugal. The agreement furthers 四色AV麓s ability to bring the benefits of continuous tableting, including reduced time to market and increased supply chain flexibility, to pharmaceutical customers globally. A presentation explaining how the technology has advanced will take place during a conference in Portugal (16鈥18 April), organized by Concept Heidelberg. Lisbon, March 18, 2024 鈥 四色AV, the specialist integrated CDMO and leader in spray drying and particle engineering, and GEA, a global leader in process technology for the pharmaceutical industry, today announced the next stage of their partnership, with new development agreements, the launch of the ConsiGma庐 CDC flex as well as the installation of a new lab-scale R&D Continuous Tableting rig in 四色AV麓s facilities in Portugal. The two companies鈥 collective and complementary knowledge of continuous tableting is being applied to streamline the technology and make it more accessible to pharmaceutical customers worldwide. The two expert teams are collaborating to bring continuous tableting to the same level of maturity as batch tableting, thereby capturing the known benefits of continuous manufacturing while reducing the downsides. The ConsiGma庐 CDC flex (patent pending), has been designed as a truly versatile system which can operate seamlessly in both continuous and batch modes and offer both high and low throughput functionality. With a focus on user-friendliness, the ConsiGma庐 range will be augmented further with new developments to simplify routine development operations and introduce automated workflows and Smart controls interfaces, empowering operators to streamline production processes. GEA will also supply 四色AV with lab-scale feeding and blending systems for research and development (R&D) applications which will bolster 四色AV鈥檚 current GMP equipment for both continuous direct compression (CDC) and wet granulation continuous tableting and complement the non-GMP test capabilities of GEA in Wommelgem. Since signing the original collaboration agreement last year, the two companies have worked predominantly on two areas of the partnership: technology development and the joint promotion of continuous tableting. Presentations explaining how the technology has advanced will take place during the continuous tableting conference in Cascais, Portugal (April 16-18), organized by Concept Heidelberg, and another event Princeton NJ, USA (September 16-18), organized by Continuous Manufacturing Forum. 鈥淲e believe that continuous tableting can offer significant benefits to our customers, not only by shortening time to market and reducing development and manufacturing costs but also by improving product quality and sustainability鈥, commented Filipe Gaspar, VP Technology Intensification at 四色AV. 鈥淭hrough our collaboration with GEA, we aim to revolutionize the continuous production of oral solid dosage forms, making the technology more accessible and efficient for pharma customers.鈥 鈥 鈥溗纳獳V and GEA benefit from a very large and complementary pool of continuous tableting experts; together, their collective knowledge is being applied to make continuous processing much less complex鈥 stated Phillip Gabb, Strategic Business Director, Pharma Solid Dosage at GEA Pharma & Healthcare. 鈥淭here is an industry perception that a lot of highly qualified and well-trained people are required to run a continuous line. The partnership鈥檚 intention is to simplify that, make it no different to running a standard tablet press and enable existing operators 鈥 with the right guidance 鈥 to use continuous manufacturing equipment.鈥  Background information About 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four鈥疐DA inspected鈥痵ites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥痙evelopment and compliant manufacture鈥痮f innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. About GEA GEA is one of the world鈥檚 largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services. With more than 18,000 employees, the group generated revenues of about EUR 5.4 billion in more than 150 countries in the 2023 fiscal year. GEA plants, processes, components and services enhance the efficiency and sustainability of customer鈥檚 production. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company鈥檚 purpose: 鈥滶ngineering for a better world鈥. GEA is listed on the German MDAX the European STOXX庐 Europe 600 Index and is among the companies comprising the DAX 50 ESG, MSCI Global Sustainability as well as Dow Jones Sustainability World and Dow Jones Sustainability Europe Indices.  

Press Release
The agreement furthers 四色AV麓s ability to bring the benefits of continuous tableting, including reduced time to market and increased supply chain flexibility, to pharmaceutical customers globally

四色AV and GEA Strengthen Partnership to Advance Continuous Tableting Technology

Mar 18, 2024

四色AV has entered into a license agreement with Dragonfly Technologies, Inc. to offer its customers the breakthrough micellar technology developed by Prof. Lipshutz. The agreement provides 四色AV with the capability to develop chemistry-in-water, enabling a significant reduction in carbon footprint compared to conventional chemical processes relying on traditional organic solvents. Lisbon, March 07, 2024, 四色AV, the specialist integrated CDMO and leader in spray drying and particle engineering, today announced it has signed an agreement with Dragonfly Technologies, Inc. to gain access to its micellar technology for chemistry-in-water processes, developed by Prof. Bruce Lipshutz of the University of California, Santa Barbara (UCSB). 四色AV will further progress the technology to make it an integral part of its API manufacturing technology offering.  Micellar chemistry enables multiple chemical transformations to take place in nanomicelles dispersed in water, mimicking natural chemical transformations. The technology allows reactions to occur at lower temperatures and enables the reduction or even the avoidance of rare and expensive metal catalysts. At the same time, by minimizing the use of organic solvents, it can also reduce the carbon footprint of the desired chemical reactions.  Dr. Jean-Luc Herbeaux, 四色AV鈥檚 CEO commented: "Manufacturing of APIs and their intermediates make up a significant proportion of the overall carbon footprint of pharmaceutical product manufacturing. Gaining access to Dragonfly鈥檚 groundbreaking micellar technology is a key step in our journey to introduce more sustainable manufacturing options at industrial scale. This proprietary process technology enables the use of less energy-intensive conditions, lower levels of precious metal-containing catalysts, and lesser use of organic solvents.鈥 Prof. Bruce Lipshutz said: 鈥淚 am delighted about the collaboration between 四色AV and Dragonfly on micellar catalysis chemistry in water. 四色AV has a long history of developing and industrializing innovative technologies for the pharma industry. This agreement will help ensure that aqueous micellar technologies will have wider and faster market adoption, benefiting the industry as a whole, by enabling development of nature-based sustainable processes in water.鈥 This collaboration is another example of 四色AV麓s commitment to expanding its technology platforms and contributing towards creating a more sustainable industry. The company is investing both in new assets and innovative technologies to meet customer demand for more sustainable integrated and differentiated development and manufacturing services for drug substances, particle engineering, and drug products. This new agreement follows on from other partnerships recently forged by 四色AV to deliver new innovative solutions to customers, including those with IDC, to offer innovative nasal delivery devices, with H&T Presspart for the advancement of a dry powder inhaler platform, with Zerion Pharma to commercialize the Dispersome庐 technology platform and with Ripple Therapeutics to expand the use of the Epidel庐 platform beyond ophthalmic applications. In addition, in November 2024 四色AV acquired ExtremoChem, a company with a portfolio of rare sugars which have shown potential in stabilizing biopharmaceuticals. Note to editor: Dragonfly Technologies, Inc. is a company founded by Prof. Bruce Lipshutz which is devoted to micellar technology. About 四色AV: 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four鈥疐DA inspected鈥痵ites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥痙evelopment and compliant manufacture鈥痮f innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.  

Press Release
The agreement provides 四色AV with the capability to develop chemistry-in-water, enabling a significant reduction in carbon footprint compared to conventional chemical processes relying on traditional organic solvents.

四色AV partners with Dragonfly Technologies to offer micellar chemistry technology to customers as a sustainable alternative to conventional chemical processes

Mar 07, 2024

四色AV has been recognized as a Top Employer in all four of its manufacturing sites, in Lisbon (Portugal), Cork (Ireland), East Windsor (NJ) and Macau. 四色AV is the first company to be certified as a Top Employer in Macau. 四色AV鈥檚 3 other sites, who had achieved Top Employer status in 2023, showed improved results this year.   Lisbon, January 18, 2024, 四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, is delighted to announce that it has been recognized as a Top Employer in all four of its manufacturing sites. 四色AV is the first ever company to be certified as a Top Employer in Macau. This marks a significant milestone in the company's commitment to fostering a supportive workplace environment and providing meaningful and rewarding roles for its team members. It also demonstrates that 鈥淥ne 四色AV鈥, a company麓s strategic initiative to give team members an equally high-quality experience across all locations, is delivering.  The certification program by the Top Employers Institute evaluates organizations through their participation in and outcomes of the HR Best Practices Survey. This comprehensive survey encompasses six domains and addresses 20 topics from Career Development to Leadership and from Employee Wellbeing to Equity & Inclusion and Wellbeing, amongst others. The program has certified and recognized over 2,300 Top Employers in 121 countries/regions across five continents.  "四色AV is a company committed to excellence and differentiation and being a Top Employer is an integral component of 四色AV's People Strategy. I am pleased to see that our continuous improvement program, supported by Top Employer麓s best practices benchmarks, resulted in our progressing along multiple dimensions at all our locations鈥, commented Ilda Ventura, Vice-President for Human Resources and Member of the Management Board of 四色AV.     Macau Special Administrative Region Douglas Lau, Human Resources Director for 四色AV Macau, said that 鈥淚t is a real achievement to be the first company in Macau to be a Top Employer. This demonstrates that companies in Macau can offer the same high quality workplace environment as anywhere else in the world. Coming so soon after 四色AV was awarded the Medal of Merit from the Macau Government, it is also a further demonstration of how 四色AV creates jobs that have real value to both our team members and the wider society. Portugal Catarina Tendeiro, HR Senior Director for 四色AV Portugal, said that 鈥淲e are thrilled to announce that 四色AV has once again been recognized as Top Employer. This is a confirmation of our ongoing commitment to developing an exceptional workplace environment for our team members, who represent our most significant resource and our company麓s main differentiator. I was especially pleased that this year鈥檚 report demonstrated improvement in several key areas, including Business and People Strategy, Leadership, Performance and Career and Learning. This demonstrates our desire to listen to feedback and to continue to improve our workplace experience.  USA Erin Tetreault, HR Director for 四色AV New Jersey said, 鈥淲e are thrilled to announce that 四色AV has once again been certified as a Top Employer. We believe that our people are our strongest asset and this certification demonstrates our ongoing commitment to create a workplace culture that goes beyond safety and quality and helps all team members to feel truly valued. I was especially pleased that this years鈥 report showed improvement in several key areas, including Leadership, Work Environment and Employee Wellbeing. This demonstrates our desire to listen to feedback and to continue to improve our workplace experience." Ireland Imelda Cummins, HR Director for 四色AV Ireland commented, 鈥淲e are delighted that 四色AV has once again been certified as a Top Employer. 四色AV麓s team members represent our strongest asset and enable us to offer our customers the high-quality products and services that 四色AV is known for. It also shows our ongoing commitment to developing a great workplace environment. I was especially pleased that this year鈥檚 report demonstrated improvement in several key areas, including Diversity, Equity & Inclusion, Learning, Sustainability and Career Development. This demonstrates our desire to listen to feedback and to continue to improve our workplace experience.   About 四色AV: 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four鈥疐DA inspected鈥痵ites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥痙evelopment and compliant manufacture鈥痮f innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About Top Employers Institute: Top Employers Institute is the global authority on recognising excellence in People Practices. We help accelerate these practices to enrich the world of work. Through the Top Employers Institute Certification Programme, participating companies can be validated, certified, and recognised as an employer of choice. In 2024, Top Employers Institute has certified more than 2300 organisations in 121 countries/regions. These certified Top Employers positively impact the lives of over 12 million employees globally.    

Press Release
四色AV has been recognized as a Top Employer in all four of its manufacturing sites, in Lisbon (Portugal), Cork (Ireland), East Windsor (NJ) and Macau.

四色AV certified as a Top Employer in all of its manufacturing sites

Jan 18, 2024

22 December, 2023, 四色AV is delighted to announce that the 四色AV Macau site has been awarded the Medal for Industrial and Commercial Merit by the Government of Macau, a Special Administrative Region of the People麓s Republic of China. The site underwent its first of many successful FDA inspections in 1987 and ever since has produced off-patent pharmaceutical actives, which are sold in the global market and boost Macau麓s exports. With 180 employees, it is the largest pharmaceutical site in Macau. Over the years, 四色AV has worked with a range of governmental departments to support the development of the pharmaceutical industry in Macau. This includes collaborating with the Macau Labor Affairs Bureau to develop the local workforce and create careers in the pharmaceutical industry. 四色AV also works with the Education and Youth Development Bureau to organize visits from schools and universities and to arrange internships within the company for students. Team members are also invited by Macau University to give lectures on good manufacturing practice (GMP) and chemical analysis. Eddy Leong, Site Manager of 四色AV Macau said: 鈥淚t is our great honor to receive this Medal of Merit. We would like to express our gratitude to the Macau SAR Government and all sectors of society for recognizing the company's nearly 40 years of presence and industrial activity in Macau. At 四色AV, our motto is 鈥淚n it for life鈥 and this award not only reflects our long and successful history in Macau, but also points to our successful future here. It also reflects our commitment to work with partner organizations to create rewarding career opportunities in life sciences.鈥 The Medals of Merit cover seven categories (Industrial and Commercial, Tourism, Education, Culture, Altruism and Sports). They are intended to reward individuals or organizations that stand out in the exercise of their professional activity.   About 四色AV: 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices.  四色AV's culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

Press Release
四色AV was recently awarded the Medal for Industrial and Commercial Merit by the Macau Government. 四色AV started its manufacturing operations in Macau in 1986, producing lifesaving off-patent pharmaceutical actives for the world.

四色AV awarded prestigious industry medal by Macau Government

Dec 22, 2023

四色AV and Industrial Design Consultancy (IDC) have entered into a joint development of an innovative nasal powder delivery device technology supporting local, systemic, and nose-to-brain drug delivery. Nasal delivery is a simple and safe alternative to conventional delivery routes for drug delivery, which offers a faster onset of action. It is also seen as a promising pathway to deliver new drugs to the brain and treat diseases of the central nervous system. Lisbon, November 29, 2023, 四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action. Additionally, it is emerging as a promising pathway to deliver new drugs to the brain to treat diseases of the central nervous system (CNS).  四色AV and IDC have been working together to accelerate the development and commercialization of two new active nasal powder delivery devices, one single-use and one multidose. The devices enable broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. By using standard capsules and filling equipment, they also have the potential to simplify drug product development and manufacturing.  "Intranasal drug delivery is gaining momentum across a number of applications, including mucosal vaccination and CNS treatments bypassing the blood-brain barrier", says Dr. Jean-Luc Herbeaux, 四色AV's CEO. He adds: "Our partnership with IDC, a company with vast experience in industrial design, mechanical and electronic engineering of medical devices, enables 四色AV to offer a complete solution for nasal powder delivery 鈥 covering Active Pharma Ingredients (APIs), formulation, filling, analytics and device design and manufacturing - that address the needs of pharmaceutical companies and patients".  鈥淏y combining 四色AV鈥檚 capabilities in pharmaceutical development, formulation and manufacturing with IDC鈥檚 device development expertise, this partnership offers customers a nasal powder delivery solution which can be rapidly adapted to new pharma compounds and therapies鈥 explains IDC麓s Managing Director, Dr Stephen Knowles, 鈥淥ur joint development team has done incredible work to create unique, high performance nasal powder delivery devices.鈥 四色AV will offer the new devices on an exclusive basis as part of its integrated offer for nasal drug development and manufacturing.    About 四色AV: 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices.  四色AV's culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About IDC: IDC is a leading medical product design and development consultancy dedicated to using its creativity, insight, experience and expertise to make the best possible products and deliver commercially successful products for clients and partners.  With over 50 years鈥 experience and ISO13485 compliant processes and facilities in London and Shanghai, IDC鈥檚 experts in user research, design, mechanical and electronics engineering and rapid prototyping work to create award-winning, world-leading products for global markets.    IDC鈥檚 track record includes many commercialized drug delivery devices across inhalation, nasal and injectables with a focus not just on design but also ensuring a smooth transition to production and regulatory approvals. IDC鈥檚 mission statement is 鈥淲e innovate to create successful products which improve people鈥檚 lives鈥.  

Press Release
四色AV, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.

四色AV expands nasal drug delivery capabilities with the development of nasal powder delivery device technology in collaboration with IDC

Nov 29, 2023

四色AV has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremophiles. The acquisition provides 四色AV with new high-performance functional materials, which have shown potential in stabilizing biopharmaceuticals. Lisbon, November 16, 2023, 四色AV, the specialist integrated CDMO and the leader in spray drying and particle engineering, today announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on the synthesis, development, and commercialization of bio-inspired synthetic sugars, targeting enhanced stabilization, reduced viscosity and delivery performance of proteins and other biopharmaceuticals.  ExtremoChem developed a library of proprietary sugars, synthetic analogues of natural molecules found in extremophiles 鈥 organisms capable of withstanding the most uninhabitable environments. These sugars have shown potential in overcoming challenges associated with the stabilization of biopharmaceuticals during production, purification, formulation, and transportation. Dr. Jean-Luc Herbeaux, 四色AV鈥檚 CEO commented: "Proteins and other biopharmaceuticals account for a significant share of our customers 麓pipelines.  The acquisition of ExtremoChem鈥檚 synthetic sugars combined with 四色AV's particle engineering capabilities provides our customers with a unique set of tools to optimize formulations that address stability issues encountered during the life cycle of biopharmaceuticals.鈥 Filipe Aguiar, ExtremoChem鈥檚 Managing Director commented: 鈥淚 am delighted that ExtremoChem has been acquired by 四色AV. 四色AV has a long history of developing and industrializing innovative technologies for the pharma industry. This acquisition will help ensure that the science we developed at ExtremoChem will have a wider and faster market adoption.鈥 The announcement of this acquisition demonstrates 四色AV麓s commitment to expand its technology platforms. The company is investing both in new assets and innovative technologies to meet customer demand for integrated and differentiated development and manufacturing services in drug substance, particle engineering and drug product.   About 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices.  四色AV's culture is based on innovation, quality, and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. 鈥 About ExtremoChem ExtremoChem is a chemical synthesis start-up company focused on the development of organic synthetic sugars for the stabilization of biologicals under stress conditions.     

Press Release
四色AV, the specialist integrated CDMO and the leader in spray drying and particle engineering, today announced it has acquired ExtremoChem Lda (ExtremoChem)

四色AV acquires ExtremoChem and its portfolio of proprietary sugars to support customers with stabilization and delivery of biopharmaceuticals

Nov 16, 2023

Lisbon, May 3, 2023 - 四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser漏 Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to develop the Sunriser漏 Dry Powder Inhaler. This innovative and best-in-class capsule-based platform is flexible enough to address both the challenges of classic carrier-based and spray-dried engineered formulations. This partnership is an extension of a successful collaboration that has spanned several years on developing and commercializing innovative dry powder inhalation devices. As part of the joint development agreement, 四色AV will exclusively partner with Presspart to exploit the Sunriser漏 device in the field of engineered formulations for dry powder inhalation. Presspart will remain responsible for the manufacturing of the Sunriser漏 device. To provide further insights into the benefits of this partnership for the industry, a joint workshop will be held today, May 3rd, at the Respiratory Drug Delivery (RDD) Europe 2023. "New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung,鈥 says Dr. Jean-Luc Herbeaux, 四色AV麓s CEO. He adds: 鈥淲e are thrilled to expand our current partnership with Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.鈥  Christian Kraetzig, President of H&T Presspart, commented 鈥淔ollowing our successful collaboration with 四色AV on the PowdAir Plus DPI device development, we are once again extremely pleased to be working with 四色AV in developing this next generation high performance DPI device. As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio within the growing field of dry powder technology.鈥 Pharmaceutical companies partnering with 四色AV to develop their new inhalable drugs using the Sunriser漏 device can leverage 四色AV麓s unparalleled expertise in inhalable APIs, formulation, filling, and analytical characterization. Additionally, with H&T Presspart's state-of-the-art device manufacturing and supply, from lab to commercial cGMP scale, companies can benefit from a comprehensive approach to drug development. This partnership enables pharmaceutical companies to access top-notch expertise and cutting-edge technology, ensuring the successful development and commercialization of innovative inhalable drugs.   About 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices.  四色AV's culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About H&T Presspart H&T Presspart is a market leading manufacturer of drug delivery devices and components with more than 50 years' experience and enjoys a worldwide reputation for competence, quality and innovation in the pharmaceutical market. With more than 30 engineers and scientists, H&T Presspart supports its customers in bringing to market new drug delivery devices. H&T Presspart has 4 European manufacturing sites in Germany, Spain, Switzerland and the UK and also has sales representation in China, India, the U.S.A. and Uruguay.     

Press Release
四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser漏 Capsule-based Dry Powder Inhaler platform.

四色AV and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery

May 03, 2023

Lisbon, March 22nd, 2023 鈥 四色AV and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon麓s expertise in 3D screen printing, based on their SPID庐-Technology, with 四色AV鈥檚 product & process development, engineering and manufacturing expertise in pharmaceutical applications. Under the terms of the agreement, 四色AV will establish the Laxxon Medical 3D screen printing technology at 四色AV鈥檚 cGMP production sites first in Portugal and later in the USA.  The 3D technology displays numerous advantages including the potential to produce unique or customized dosage forms with characteristics that cannot be achieved with conventional dosage forms, the ability to create tablets of any shape and size, the option to easily adjust the number of active substances and individual components in the composition of the tablet and even to set the dosage individually for each patient for personalized medicines. 鈥淟axxon is thrilled to establish a long-term partnership with 四色AV.鈥 said Klaus Kuehne, COO of Laxxon Medical. 鈥淭his partnership will serve as a great accelerator in establishing 3D screen printing within the pharmaceutical industry thus accelerating our ability to serve our customers.鈥 鈥溗纳獳V has a global reputation for their pharmaceutical innovation services, expertise and market access. This agreement marks a significant milestone for Laxxon in terms of our own market strategy and development efforts.鈥 said Helmut Kerschbaumer, Laxxon鈥檚 CEO. 鈥淲e are looking forward to collaborating with 四色AV to promote innovation through 3D screen printing.鈥  鈥淲e find the Laxxon Medical 3D printing technology to be very innovative and enabling. It not only allows for the customization and production of drug products with complex shapes and structures as well as unique API release characteristics but it also has the potential to reduce the time and cost of drug development鈥 says Dr. Jean-Luc Herbeaux, 四色AV麓s CEO. He adds 鈥溗纳獳V has a track record of turning emerging pharmaceutical production technologies into reliable and scalable offerings at both developmental and commercial scales. We are excited at the prospect of supporting Laxxon in industrializing its 3D printing technology and make it accessible to a greater number of pharmaceutical and medical device companies.鈥 With this partnership the platform will be available from early development phases to routine commercial manufacturing.        About Laxxon Medical Laxxon Medical is a pharma-technology company pioneering patented cutting-edge 3D screen printing development and manufacturing solutions for the pharmaceutical industry. Laxxon鈥檚 SPID庐-Technology (Screen Printing Innovational Drug Technology) facilitates different pharmaceutical forms of application such as oral, transdermal, and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients, enabling different release profiles such as sequential release. SPID庐-Technology is capable of printing small batches for R&D, up to commercial-scale production without the need to change the manufacturing process. SPID庐-Technology (3D Screen Printing) SPID庐-Technology (Screen Printed Innovative Drug Technology) is an additive manufacturing process which enables the development and production of complex formulations and geometrical structures of oral dosage forms to optimize the release profiles of common pharmaceuticals in addition to new drug developments.    About 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices. 四色AV麓s culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.    

Press Release
This partnership will create an opportunity for the pharmaceutical industry to develop and manufacture clinical materials and secure industrial scale production under cGMP with 四色AV, using Laxxon Medical鈥檚 3D screen printing technology.

四色AV and Laxxon Medical Establish an Agreement for the cGMP Production of 3D Screen Printed Pharmaceutical Applications

Mar 22, 2023

Lisbon, March 20, 2023, 四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel庐 platform beyond ophthalmic applications.    The core feature of Ripple鈥檚 Epidel庐 technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel庐 platform into its toolbox, 四色AV can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry.   鈥淭he combination of technology synergy, innovative vision and cultural fit makes collaborating with 四色AV an exciting next step in the advancement of the Epidel庐 platform beyond the ophthalmic field,鈥 stated Dr. Wendy Naimark, Ripple co-founder and Chief Technology Officer. 鈥溗纳獳V鈥檚 expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.鈥   "We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," says Dr. Jean-Luc Herbeaux, 四色AV's CEO. " Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide." By extending the use of the Epidel庐 platform beyond ocular applications, this partnership will enable the development of a diverse range of new products with optimal sustained release profiles.    鈥嬧嬧嬧嬧婣bout 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices. 四色AV麓s culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About Ripple Therapeutics Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple鈥檚 Epidel鈩 technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple鈥檚 novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development. www.rippletherapeutics.com    

Press Release
四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics have entered a strategic partnership to expand the use of Ripple's Epidel庐 platform beyond ophthalmic applications.

四色AV and Ripple Enter Strategic Partnership to Expand Epidel庐 Platform into Non-Ophthalmic Space

Mar 20, 2023

Lisbon, March 8th, 2023 鈥 四色AV, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award across all six categories 鈥 capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). 四色AV was given additional recognition as a CDMO Leadership Award Champion in the categories of Compatibility and Expertise for scoring as a top performer in comparison to the weighted average of other CDMOs included in the Industry Standard Research (ISR)鈥檚 annual Contract Manufacturing Quality Benchmarking survey.  Established in 2011 by Outsourced Pharma and Life Science Leader, the CDMO Leadership Awards spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The CDMO Leadership Awards teamed up with ISR to determine the award recipients - 72 contract manufacturers were assessed by 23 performance metrics in ISR鈥檚 annual Contract Manufacturing Quality Benchmarking survey.  "We are honored and proud to receive this award in all six categories. This broad recognition reflects the dedication of our team to help our customers deliver much-needed medicines to the market," said Dr. Jean-Luc Herbeaux, 四色AV鈥檚 CEO. 鈥淭his is not the first time 四色AV is recognized by the CDMO Leadership awards and winning these awards once again reinforces our commitment to excellence and differentiation in the services we provide to our customers.鈥  鈥淔or over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold medalists of outsourcing.鈥 Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. 四色AV has been expanding worldwide, demonstrating the commitment to its customers. 四色AV has been investing in new laboratory and production assets and innovative technologies to meet customer demand for integrated and differentiated services in manufacturing of drug substances, particles and drug products.  鈥嬧嬧嬧嬧嬧 鈥嬧嬧嬧嬧婣bout 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices. 四色AV麓s culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.  

Press Release
四色AV won the 2023 CDMO Leadership Award聽across all six categories across all three groups of respondents

四色AV receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise

Mar 07, 2023

January 17, 2023, the companies certified as 2023 Top Employers have just been announced and 四色AV has been recognized as Top Employer in Portugal, the United States of America and Ireland, geographies that encompass 90% of 四色AV麓s employee population. The 四色AV site in Macau was purposely not included in the evaluation due to COVID-related restrictions.     This certification is a recognition of 四色AV麓s resolve to put people first, and a validation that the investment in HR excellence is delivering. 四色AV鈥檚 People Strategy roadmap is focused on attracting and retaining the best to support the company麓s business ambitions, and on providing employees and managers with a positive and rewarding work experience.   The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. This survey covers six domains covering 20 topics including People Strategy, Work Environment, Talent Acquisition, Learning, Diversity, Equity & Inclusion and Wellbeing, amongst others.   "Receiving this certification is a great motivator for the entire organization and most particularly for our HR Team which has been focusing on establishing best practices and on delivering on our people agenda. It is the confirmation that, as an organization, we are on the right path to make the difference. We understand that while we are not yet excellent in all dimensions, we are committed to maintaining a process of continuous improvement, by putting our people at the center of everything we do, always!" - commented Ilda Ventura, Vice-President for Human Resources and Member of the Management Board at 四色AV.   Portugal Catarina Tendeiro, HR Senior Director for Portugal, highlights that 鈥淲e are delighted to be recognized as a Top Employer. 四色AV employees are our greatest asset and to know that our programs and culture meet such a high standard is illustrative of our commitment to the team. We strive to be an employer of choice through competitive pay, meaningful work, and an attractive company culture. At 四色AV Portugal, our primary focus has been on attracting and retaining talent to develop our leadership capabilities. Over the last years we have increased pay levels and most recently, provided a special inflation bonus to counter the impact of inflation on our employees. These are just a few examples of how we put our employees in the center of what we do.鈥  This recognition comes after 四色AV received the Randstad Employer Brand Award 2022 as the most attractive company to work for in Portugal in Healthcare, ranking 5th nationally across industries.     Ireland For Imelda Cummins, HR Director for 四色AV Ireland, 鈥淭his recognition underlines our belief that our people are our strongest asset and competitive advantage. At 四色AV Ireland we work consistently to ensure competitive compensation and benefits, invest in the creation of a healthy work environment, promote regular wellbeing initiatives and most importantly, to improve, we listen!鈥     United States of America Beth Swiezkowski, HR Senior Director for 四色AV in New Jersey adds, 鈥淲e are delighted to be recognized as a Top Employer. 四色AV employees are our greatest asset and to know that our programs and culture meet such a high standard is illustrative of our commitment to the team. We strive to be an employer of choice through competitive pay, meaningful work, and an attractive company culture. Over the last year we have increased pay levels and most recently, provided a special inflation bonus to counter the impact of inflation on our employees. We focused on employee well-being and engaged experts to deliver programs on managing stress, nutrition, and healthy eating and provided free healthy snacks daily. A paid full week shutdown was also added to our holiday schedule to ensure employees had time to relax and rest with their families at the end of the year. These are just a few examples of how we put our employees in the center of what we do.鈥       About 四色AV 四色AV is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China as well as development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solution across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices. 四色AV麓s culture is based on innovation, quality and delivery. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About Top Employers Institute Top Employers Institute is the global authority on recognising excellence in People Practices. They help accelerate these practices to enrich the world of work. Through the Top Employers Institute Certification Programme, participating companies can be validated, certified, and recognised as an employer of choice. Established over 30 years ago, Top Employers Institute has certified 2052 organisations in 121 countries/regions. These certified Top Employers positively impact the lives of over 9.5 million employees globally.       

Press Release
This certification is a recognition of 四色AV麓s resolve to put people first, and a validation that the investment in HR excellence is delivering.

四色AV is recognized as a Top Employer 2023

Jan 17, 2023

Lisbon, December 14, 2022, 四色AV and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA麓s engineering expertise with 四色AV麓s development and manufacturing experience and both parties commit to partner to accelerate the adoption of Continuous Tableting technology. The advantages of continuous over batch manufacturing are well known. Continuous production systems allow for leaner and risk-reduced development paths, leaner supply chains, increased built-in quality, and in general, manufacturing processes of greater flexibility and reduced complexity. In the context of this strategic collaboration, 四色AV and GEA will combine their strengths to further advance the technology and contribute to the establishment of new standards and new levels of market acceptance.  鈥溗纳獳V has a track record in industrializing and democratizing emerging pharmaceutical technologies, such as amorphous solid dispersions by spray drying, and turn them into dependable and scalable offerings that are available to all.鈥 Says Jean-Luc Herbeaux, CEO of 四色AV. He adds 鈥淲e have been committed to Continuous Tableting for the last 7 years and we are now ready to contribute decisively to the advancement of one of the most promising technologies in pharma manufacturing. This collaboration with GEA, gives us the opportunity to link up with a leading designer and supplier of Continuous Tableting equipment solutions and bring Continuous Tableting to the next levels of reliability, flexibility and adoption.鈥  Navin Lakhanpaul, Global Head Pharma-Solid Dosage, GEA, adds: 鈥淎s a leading supplier of process technology, GEA has established itself as a trusted solution provider in the pharmaceutical industry, and as a pioneer in the development of Continuous Tableting technology.鈥 He adds 鈥淥ur relationship with 四色AV over many years has clearly demonstrated the value in further collaborating and developing synergies in our respective areas of expertise. We share a common objective of enabling the wider use of Continuous Tableting in the Pharmaceutical Industry, and firmly believe that our partnership with 四色AV will accelerate the growth of this exciting technology."     About 四色AV: 四色AV is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USA, China, Ireland, and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of and services, from API, formulation development and devices. 四色AV was the first Chemical/ Pharmaceutical Company to became a Certified B Corp, is a member of Rx-360, EFCG and participates actively in the industry standard setting process.   About GEA: GEA is one of the world's largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology卢 group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components, and comprehensive services. With more than 18,000 employees working across five divisions and 62 countries, the group generated revenues of more than EUR 4.7 billion in fiscal year 2021. GEA plants, processes, components and services enhance the efficiency and sustainability of production processes across the globe. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company鈥檚 purpose: "Engineering for a better world". GEA is listed in the German MDAX and the STOXX庐 Europe 600 Index and is also among the companies comprising the DAX 50 ESG and MSCI Global Sustainability Indices.     Learn more about Continuous Tableting at 四色AV  

Press Release
四色AV and GEA today announced a strategic collaboration to advance Continuous Tableting.

四色AV and GEA announce a strategic collaboration to advance Continuous Tableting

Dec 14, 2022

Lisbon, 6th September 2022 鈥 四色AV, the leader in spray drying and particle engineering, announced today that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal. In addition, to support 四色AV鈥檚 commitment to providing access and services for continuous tableting, 四色AV has further strengthened its capabilities by establishing a highly experienced multi-disciplinary global team in continuous tableting and upgrading its labs with the tools needed to support the drug product lifecycle, thereby further guaranteeing competency and capacity from research & development to commercial production. 聽 Continuous manufacturing is expected to change the landscape of drug product development and commercial production. The Food and Drug Administration (FDA) is partnering with the International Council for Harmonization and leading a global initiative to advance continuous manufacturing of small molecules and other pharmaceutical modalities. 四色AV is offering customers a commercial continuous tableting platform prepared to support key control needs and deliver on operational excellence, mechanistic modeling, and appropriate process analytical technology (PAT). Additionally, 四色AV麓s quality system has been designed to support the release of continuous tableting products through automated in-process controls, deployment of real time release, and compliant digital infrastructure. This cutting-edge technology offers a distinct set of features and advantages including faster development of simpler processes, agile manufacturing for variable demand, robust control strategies and high process quality standards.聽 鈥溗纳獳V has been historically focused on innovative technologies that benefit our customers and patients. With this investment in continuous tableting, our customers can rely on our support to bring much needed medicines to the market as fast as possible with the highest quality and manufacturing standards.鈥, comments Jean-Luc Herbeaux, 四色AV麓s CEO. 鈥淲e are investing to accelerate the adoption of this technology as we continue to innovate and enhance our offering around our areas of expertise.鈥 聽 鈥淭his investment in continuous tableting from R&D to production further strengthens 四色AV麓s CDMO offering and responds to the growing customer interest.鈥 says Filipe Neves, 四色AV麓s Strategic Business Director.聽 This latest investment in Continuous Tableting is part of 四色AV麓s broader strategy to build differentiated and enabling capabilities and assets to meet customers unique needs for oral dosage forms manufacturing. 聽 About 四色AV:聽四色AV is an international company with over 60 years of experience as a聽Contract Development and Manufacturing Organization聽(CDMO)聽with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the聽development and compliant manufacture聽of innovative drugs, including highly potent compounds, and customized product solution across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices. 四色AV麓s culture is based on innovation, quality and delivery. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. 聽

Press Release
四色AV, the leader in spray drying and particle engineering, announced today that it has expanded its continuous manufacturing offering and services.

四色AV expands drug product offering with a new manufacturing line dedicated to Continuous Tableting

Sep 06, 2022

Contact Us

If you would like to learn more about 四色AV, kindly fill in the form below and we will be revert to you soon.